CATX — Perspective Therapeutics, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 728387 ·
Last close
$0.86
Market Cap
$103.84M
52W High
$6.16
52W Low
$0.78
ADV30
3,499,672
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -34,322,000 | -32,442,000 | 365,682,000 | 41,042,000 | 71,002,000 |
| Jun 2026 | 0 | — | -29,258,000 | -26,786,000 | 392,025,000 | 48,488,000 | 68,162,000 |
| Mar 2026 | 0 | — | -28,281,000 | -26,189,000 | 410,769,000 | 53,972,000 | 63,331,000 |
| Dec 2025 | 0 | — | -39,832,000 | -37,490,000 | 266,972,000 | 30,629,000 | 59,941,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-108,127,000
Investing CF
$-42,266,000
Financing CF
$164,673,000
CapEx
$-30,663,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.09
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-387,815,000
Inventory
—
Receivables
$269,000
ST Investments
$188,388,000
EBIT TTM
$-117,119,000
Pretax Income TTM
$-117,424,000
Interest Exp TTM
$305,000
Analysts
14
Yahoo Snapshot (yfinance, live)
Total Revenue
$220,000
EBITDA
$-127,229,000
Free Cash Flow
$-78,374,248
Enterprise Value
$-84,127,360
Total Cash
$201,695,008
Total Debt
$3,680,000
Shares Out
120,758,815
Trailing EPS
$-1.25
Book Value
$2.58
ROE
-45.9%
ROA
-24.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -113,564,000 | -103,121,000 | 266,972,000 | 59,941,000 | 207,031,000 | -82,484,000 |
| Dec 2024 | 0 | -66,797,000 | -79,279,000 | 341,101,000 | 50,433,000 | 290,668,000 | -18,294,000 |
| Dec 2023 | 0 | -40,941,000 | -46,508,000 | 97,891,000 | 22,712,000 | 75,179,000 | -36,913,000 |
| Jun 2022 | 10,795,000 | -7,391,000 | -7,272,000 | 64,439,000 | 3,162,000 | 61,277,000 | -7,710,000 |
TTM Snapshot
Revenues TTM
$8,115,000
NetIncome TTM
$-116,434,000
OpCashFlow TTM
—
Assets (Latest)
$392,025,000
Forward EPS
$-1.03
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OKUR | OnKure Therapeutics, Inc. | $104.50M | $2.58 | — |
| NERV | Minerva Neurosciences, Inc. | $103.13M | $2.16 | — |
| ORGO | Organogenesis Holdings Inc. | $105.35M | $0.81 | — |
| OGI | ORGANIGRAM GLOBAL INC. | $101.90M | $0.71 | — |
| NRXP | NRX Pharmaceuticals, Inc. | $106.07M | $2.45 | — |
News headlines (Yahoo Finance, 1h cache)
Perspective Therapeutics: Q3 Earnings Snapshot
2026-11-09 21:56 · Yahoo
Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 Results
2026-11-09 21:30 · Yahoo
Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs
2026-11-06 01:10 · Yahoo
Perspective Therapeutics (CATX) Stock Sees Fair Value Moves Lower As Analysts Weigh Lead 212 Risks
2026-11-01 02:12 · Yahoo
Perspective Therapeutics Posts 72% 18-Month PFS in VMT-α-NET Study Update
2026-10-23 21:02 · Yahoo
Perspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced
2026-10-23 14:49 · Yahoo
Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors
2026-10-08 10:16 · Yahoo
Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026
2026-10-02 15:46 · Yahoo
Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
2026-09-14 10:16 · Yahoo
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026
2026-09-11 10:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.